TD Capital Management’s Coherus Oncology CHRS Stock Holding History

TD Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	–	–	137
2021 Q4	$0	Hold	10	–	–	﹤0.01%	378
2021 Q3	$0	Hold	10	–	–	﹤0.01%	366
2021 Q2	$0	Buy	+10	New	+$142	﹤0.01%	347

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TD Capital Management's CHRS Position: Q1 2022 in Review

TD Capital Management sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 10 shares.

TD Capital Management first reported a position in CHRS in Q2 2021 and held it in 3 quarters. The position peaked at $0 in Q4 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

TD Capital Management reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
TD Capital Management sold 10 Coherus Oncology shares in Q1 2022.
TD Capital Management first reported a position in Coherus Oncology in Q2 2021 and held it in 3 quarters.
TD Capital Management's Coherus Oncology position peaked at $0 in Q4 2021.
183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on TD Capital Management's 13F filing for Q1 2022, filed 18 May 2022.